Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells

International Journal of Pharmaceutics

Volumn 361, Issue 1-2, 2008, Pages 239-244

  Zhang, Xing Guo ^a   Miao, Jing ^a   Dai, You Qin ^c   Du, Yong Zhong ^b   Yuan, Hong ^b   Hu, Fu Qiang ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c NINGBO NO 2 HOSPITAL   (China)

Author keywords

Cytotoxicity; Doxorubicin; Multi drug resistance; Nanostructured lipid carriers; Paclitaxel

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; FOLIC ACID; GLYCEROL STEARATE; LIPID; NANOPARTICLE; OLEIC ACID; PACLITAXEL; POLOXAMER; SOLVENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DIFFUSION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PARTICLE SIZE; PRIORITY JOURNAL; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIFFUSION; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; GLYCERIDES; HUMANS; NANOSTRUCTURES; OLEIC ACID; PACLITAXEL; SOLVENTS; STEARIC ACIDS;

EID: 47949106574     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.06.002     Document Type: Article

References (20)

1. Antonella M., Roberta C., Claudia B., and Ludovica G. Cellular uptake and cytotoxicity of solid nanospheres (SLN) incorporatin doxorubicin or paclitaxel. Int. J. Pharm. 210 (2000) 61-67
2. Barraud L., Merle P., and Soma E. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular cancer cells in vitro and in vivo. J. Hepatol. 42 (2005) 736-743
3. Davda J., and Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233 (2002) 51-59
4. Goren D., Horowitz A.T., Tzemach D., et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multi-drug-resistance efflux pump. Clin. Cancer Res. 6 (2000) 1949-1957
5. Gupta A.K., Gupta M., Yarwood S.J., and Curtis A.S.G. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. J. Control. Release 95 (2004) 197-207
6. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., and Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B Biointerfaces 45 (2005) 167-173
7. Hu F.Q., Jiang S.P., Du Y.Z., et al. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm. 314 (2006) 83-89
8. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain cancers. J. Control. Release 99 (2004) 259-269
9. Lee E.S., Na K., and Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 cancer. J. Control. Release 103 (2005) 405-418
10. Lo Y.L., Liu F.I., Yang J.M., and Cherng J.Y. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anticancer Res. 21 (2001) 445-450
11. Mahesh D.C., Yogesh P., and Jayanth P. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm. 320 (2006) 150-156
12. Mechetner E., Kyshtoobayeva A., Zonis S., et al. Levels of multi-drug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 4 (1998) 389-398
13. Miglietta A., Cavalli R., Bocca C., Gabriel L., and Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210 (2000) 61-67
14. Nemati F., Dubernet C., and Fessi H. Reversion of multi-drug resistance using nanoparticles in vitro: influence of the nature of the polymer. Int. J. Pharm. 138 (1996) 237-246
15. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580 (2006) 2903-2909
16. Serpea L., Catalanob M.G., and Cavalli R. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58 (2004) 673-680
17. Sharma E., Mayhew R., and Straubinger M. Anticancer effect of taxolcontaining liposomes in a taxol-resistant murine cancer model. Cancer Res. 53 (1993) 5877-5881
18. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., and Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348 (2008) 137-145
19. Zauner W., Farrow N.A., and Haines A.M. In vitro uptake of polystyrene microspheres: effect of particle size cell line and cell density. J. Control. Release 71 (2001) 39-51
20. Zhou C.G., Shen P., and Cheng Y.Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim. Biophys. Acta 7 (2007) 1011-1020